Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A compound of the formula:



Formula I

wherein ,

Y represents CH_2 or O;

R1 and R2 each independently represent hydrogen or flouro

R3 represents a group of the formula:



wherein Z represents (CH2)n or –CR4R5-CH2-;

n represents 0-3; and

Het represents a group of the formula:



R4 and R5 each independently represent at each occurrence hydrogen or methyl;

R6 and R7 each independently represent at each occurrence hydrogen, methyl, or ethyl; provided Formula I does not represent a compound selected from the group consisting of


,

,

,

,

,

,

and

;

or a pharmaceutically acceptable salt thereof.

2. (Original) The compound according to Claim 1 wherein R ^{1} represents hydrogen.

3. (Original) The compound according to Claim 1 wherein R^1 represents fluoro.

4. (Previously Presented) The compound according to Claim 1 wherein R^2 represents hydrogen.

5. (Previously Presented) The compound according to Claim 1 wherein R^2 represents fluoro.

6. (Previously Presented) The compound according to Claim 1 wherein R^3 represents a group of the formula:

wherein Z represents (CH2)n or –CR4R5-CH2-;

n represents 0-3; and

Het represents a group of the formula:



7. (Original) The compound according to Claim 6 wherein Het represents a group of the formula:



8. (Original) The compound according to Claim 6 wherein Het represents a group of the formula:



9. (Previously Presented) The compound according to Claim 6 wherein R^3 represents a group of the formula:



10. (Original) The compound according to Claim 9 wherein R^3 represents a group of the formula:



11. (Original) The compound according to Claim 9 wherein R^3 represents a group of the formula:



12. (Previously Presented) The compound according to Claim 1 wherein R^3 represents a group of the formula:

13. (Original) The compound according to Claim 12 wherein R^3 represents a group of the formula:



14. (Previously Presented) A pharmaceutical composition comprising the compound according to Claim 1 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

15. (Withdrawn) A method of treating a disorder selected from the group consisting of Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic congestive heart failure (CHF), peripheral vascular disease, diabetic nephropathy,

cirrhosis with edema and ascites, esophageal varicies, Addison's Disease, muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Th1/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hyperglycemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema, multiform, cutaneous T-cell lymphoma, psychoses, cognitive disorders, memory disturbances, mood disorders, depression, bipolar disorder, anxiety disorders, and personality disorders, comprising administering to a patient in need thereof a compound as claimed in Claim 1, or a pharmaceutically acceptable salt thereof.

16. (Withdrawn) The method according to Claim 15 wherein the disorder is selected from the group consisting of is diastolic or systolic congestive heart failure, inflammation, rheumatoid arthritis, an autoimmune disorder, asthma, or chronic obstructive pulmonary disease.

17. (Withdrawn) The method according to Claim 16 wherein the disorder is diastolic or systolic congestive heart failure, inflammation, or rheumatoid arthritis.

18. (Cancelled)

19. (Cancelled)

20. (New) The compound according to Claim 1 selected from the group consisting of 5-(3,7-Difluoro-6H-dibenzo[b,e]oxepine-11-ylidenemethyl)-1-(1-methyl-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-one, E-isomer; 5-(3-Fluoro-6H-dibenzo[b,e]oxepin-11-ylidenemethyl)-1-(1-methyl-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-one, E isomer; 5-(3,8-Difluoro-6H-dibenzo[b,e]oxepin-11-ylidenemethyl)-1-(1-methyl-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-one, E isomer; (R)-5-(3-fluoro-6H-dibenzo[b,e]oxepin-11-ylidenemethyl)-1-[1-(1-methyl-2-morpholin-4-yl-ethyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one, E isomer; and (R)-5-(3,7-difluoro-6H-dibenzo[b,e]oxepin-11-ylidenemethyl)-1-(1-methyl-pyrrolidin-3-yl)-1,3-dihydro-H-benzoimidazol-2-one, E isomer.